A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice. [PDF]
PLoS Neglected Tropical Diseases, 2015 BACKGROUND:Vibrio cholerae is the cause of cholera, a severe watery diarrhea. Protection against cholera is serogroup specific. Serogroup specificity is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS).
Md Abu Sayeed +19 more
doaj +1 more source
Socio-cultural determinants of anticipated acceptance of an oral cholera vaccine in Western Kenya [PDF]
, 2017 Determinants of anticipated acceptance of an oral cholera vaccine (OCV) were studied in urban and rural communities of Western Kenya. An explanatory model interview administered to 379 community residents assessed anticipated vaccine acceptance at ...
CHAIGNAT, C.-L +6 more
core +2 more sources
Oral cholera vaccines and their impact on the global burden of disease
Human Vaccines & Immunotherapeutics, 2019 With one-third of nations at risk of cholera, we can expect to experience massive, rapidly disseminated, and prolonged cholera outbreaks such as those recently experienced in Yemen and Haiti.
Thomas F. Wierzba
doaj +1 more source
Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. [PDF]
PLoS Neglected Tropical Diseases, 2012 Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine. Balancing this concern is the
Ramadhan Hashim +24 more
doaj +1 more source
Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. [PDF]
PLoS Neglected Tropical Diseases, 2011 BACKGROUND: Killed oral cholera vaccines (OCVs) are available but not used routinely for cholera control except in Vietnam, which produces its own vaccine.
Dang Duc Anh +9 more
doaj +1 more source
Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study
The Lancet Global Health, 2016 Background: Oral cholera vaccines represent a new effective tool to fight cholera and are licensed as two-dose regimens with 2–4 weeks between doses.
Dr. Andrew S Azman, PhD +24 more
doaj +1 more source
Stemming cholera tides in Zimbabwe through mass vaccination
International Journal of Infectious Diseases, 2020 Background: In 2018, Zimbabwe declared another major cholera outbreak a decade after recording one of the worst cholera outbreaks in Africa. Methods: A mathematical model for cholera was used to estimate the magnitude of the cholera outbreak and ...
Zindoga Mukandavire +5 more
doaj +1 more source
Dynamic interactions of a conserved enterotoxigenic Escherichia coli adhesin with intestinal mucins govern epithelium engagement and toxin delivery [PDF]
, 2016 At present, there is no vaccine for enterotoxigenic Escherichia coli (ETEC), an important cause of diarrheal illness. Nevertheless, recent microbial pathogenesis studies have identified a number of molecules produced by ETEC that contribute to its ...
Bhullar, Kirandeep +7 more
core +2 more sources
Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial. [PDF]
PLoS Medicine, 2016 Vaccinating a buffer of individuals around a case (ring vaccination) has the potential to target those who are at highest risk of infection, reducing the number of doses needed to control a disease. We explored the potential vaccine effectiveness (VE) of
Mohammad Ali +11 more
doaj +1 more source
The influence of immunomodulators on the formation of vaccine-induced cholera immunity
Журнал микробиологии, эпидемиологии и иммунобиологии, 2022 Introduction. Due to the remaining tense situation on cholera in the world, research continues on the creation of new preventive drugs, as well as ways to increase the immunogenicity of existing anti-cholera vaccines.
A. V. Filippenko +3 more
doaj +1 more source